[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638807":3},{"organization":4,"outcomesModule":7,"designInfo":43,"detailedDescription":50,"studyPopulation":46,"armGroups":51,"interventions":81,"overallOfficials":105,"centralContacts":110,"locations":116,"responsibleParty":135,"collaborators":137,"id":142,"slug":143,"hasResults":144,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":150,"sex":151,"minAge":152,"maxAge":153,"enrollmentInfo":154,"targetDuration":46,"studyType":157,"phases":158,"briefSummary":160,"conditions":161,"keywords":46,"overallStatus":163,"whyStopped":46,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":173},{"fullName":5,"class":6},"University of Utah","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":17,"otherOutcomes":39},[9,13],{"measure":10,"description":11,"timeFrame":12},"Stage 1: Completion of eligibility assessment","To evaluate patient-level interventions with respect to increasing completed assessments in Stage 1.\n\nThe outcome measure will report the proportion of participants who complete the LCS eligibility assessment.","up to 18 weeks",{"measure":14,"description":15,"timeFrame":16},"Stage 2: Completion of LCS","To evaluate patient-level interventions with respect to increasing completed LCS in Stage 2.\n\nThe outcome measure will report the proportion of participants who complete LCS.","up to 30 weeks",[18,21,24,27,30,33,36],{"measure":19,"description":20,"timeFrame":16},"Cost-effectiveness: Incremental Cost","To evaluate the cost-effectiveness of the interventions in Stage 1 and Stage 2.\n\nIncremental cost-effectiveness ratios (ICER) will be constructed for Stage 1 and 2 among participants. The ICER estimates the additional resource consumption needed to successfully attain an additional unit of an outcome (e.g., completed assessment in Stage 1, completed LCS in Stage 2) using one intervention relative to another. Cost-Effectiveness Analysis (CEA) will determine the most cost-effective combination of strategies to increase reach across Stages.",{"measure":22,"description":23,"timeFrame":16},"Cost-effectiveness: Incremental Effectiveness","To evaluate the cost-effectiveness of the interventions in Stage 1 and Stage 2.\n\nIncremental cost-effectiveness ratios (ICER) will be constructed for Stage 1 and 2 among participants. The ICER estimates the additional resource consumption needed to successfully attain an additional unit of an outcome (e.g., completed assessment in Stage 1, completed LCS in Stage 2) using one intervention relative to another. CEA will determine the most cost-effective combination of strategies to increase reach across Stages.",{"measure":25,"description":26,"timeFrame":12},"Proportion of patients who engage with interventions","The outcome measure will report the proportion of participants who engage with interventions. This outcome measure is only applicable in Stage 1.",{"measure":28,"description":29,"timeFrame":16},"Proportion of patients who reply opting out of receiving interventions","The outcome measure will report the proportion of participants who reply to opt out of receiving interventions.",{"measure":31,"description":32,"timeFrame":12},"Proportion of patients who complete SDM","The outcome measure will report the proportion of participants who complete SDM. This outcome measure is only applicable in Stage1.",{"measure":34,"description":35,"timeFrame":16},"Proportion of patients who request to speak with a patient navigator","The outcome measure will report the proportion of participants who request to speak with a patient navigator. This outcome measure is only applicable in Stage 2.",{"measure":37,"description":38,"timeFrame":16},"Proportion of patients who speak with a patient navigator","The outcome measure will report the proportion of participants who speak with a patient navigator. This outcome measure is only applicable in Stage 2.",[40],{"measure":41,"description":42,"timeFrame":16},"Baseline Characteristics that predict outcomes or moderate intervention effects","This outcome measure will assess characteristics of participants that predict outcomes and\u002For moderate intervention effects.\n\nTo evaluate effect modification in Stages 1 and 2 with respect to smoking status, gender, sex as a biological variable, age, race\u002Fethnicity, partner status, social vulnerability index, and insurance status.",{"allocation":44,"interventionModel":45,"interventionModelDescription":46,"primaryPurpose":47,"observationalModel":46,"timePerspective":46,"maskingInfo":48},"RANDOMIZED","SEQUENTIAL",null,"PREVENTION",{"masking":49,"maskingDescription":46,"whoMasked":46},"NONE","LungSMART is a Sequential Multiple Assignment Randomized Trial (SMART) conducted in Utah Community Health Centers (CHCs). The SMART design is structured in two sequential stages: Stage 1 aims to increase uptake of Lung Cancer Screening (LCS) eligibility assessment, while Stage 2 aims to increase LCS completion.\n\nIn Stage 1, the Eligibility Assessment Stage, LungSMART Utah uses Azara, a population health management software, to identify potentially eligible patients from participating CHCs. Patients who are enrolled in the study will be randomized to digital health interventions and connected with a centralized hub (Hub) for eligibility assessment and shared decision making (SDM) with a qualified registered nurse (RN).\n\nIn Stage 2, the LCS Completion Stage, participants referred for LCS receive access to a Chatbot and are randomized to receive reactive (patient needs to request navigation) vs proactive (navigator proactively calls the patient) patient navigation (PN) delivered via telehealth by a community health worker (CHW) at the Hub to address logistical barriers and hesitancy in completing LCS.",[52,57,62,67,71,76],{"label":53,"type":6,"description":54,"interventionNames":55},"Stage 1: Repeated Text Messages (TM+)","Participants will receive up to nine text messages containing eligibility questions, along with up to nine reminder messages. If a participant successfully responds to the eligibility questions, no more messages will be sent. If a participant does not respond to the eligibility questions after receiving a text message, they will receive a reminder message three days later, prompting them to answer the questions.",[56],"Behavioral: Text Messages (TM+)",{"label":58,"type":6,"description":59,"interventionNames":60},"Stage 1: Repeated Text Messages and Chatbot (TM+\u002FCA)","Participants will receive up to nine text messages containing eligibility questions, along with up to nine reminder messages. If a participant successfully responds to the eligibility questions, no more messages will be sent. If a participant does not respond to the eligibility questions after receiving a text message, they will receive a reminder message three days later, prompting them to answer the questions.\n\nParticipants will have access to a Lung Cancer Screening (LCS) Chatbot delivered via Short Message Service (SMS).",[56,61],"Behavioral: Chatbot (CA)",{"label":63,"type":6,"description":64,"interventionNames":65},"Stage 1: Repeated Text Messages and Video (TM+\u002FVID)","Participants will receive up to nine text messages containing eligibility questions, along with up to nine reminder messages. If a participant successfully responds to the eligibility questions, no more messages will be sent. If a participant does not respond to the eligibility questions after receiving a text message, they will receive a reminder message three days later, prompting them to answer the questions.\n\nParticipants can watch an educational video via SMS.",[56,66],"Behavioral: Video (VID)",{"label":68,"type":6,"description":69,"interventionNames":70},"Stage 1: Repeated Text Messages, Chatbot, and Video (TM+\u002FCA\u002FVID)","Participants will receive up to nine text messages containing eligibility questions, along with up to nine reminder messages. If a participant successfully responds to the eligibility questions, no more messages will be sent. If a participant does not respond to the eligibility questions after receiving a text message, they will receive a reminder message three days later, prompting them to answer the questions.\n\nParticipants will have access to a Lung Cancer Screening (LCS) Chatbot delivered via SMS.\n\nParticipants can watch an educational video via SMS.",[56,61,66],{"label":72,"type":6,"description":73,"interventionNames":74},"Stage 2: Chatbot and Reactive Patient Navigation (CA\u002FRPN)","Reactive Patient Navigation (RPN) requires the participant to initiate the patient navigation (PN) request.\n\nParticipants receive up to three text messages scheduled four weeks apart.",[61,75],"Behavioral: Reactive Patient Navigation (RPN)",{"label":77,"type":6,"description":78,"interventionNames":79},"Stage 2: Chatbot and Proactive Patient Navigation (CA\u002FPPN)","Proactive Patient Navigation (PPN) does not require the participant to initiate the PN request and instead is a proactive call to the participant.\n\nParticipants receive up to three text messages scheduled four weeks apart.",[61,80],"Behavioral: Proactive Patient Navigation (PPN)",[82,87,93,97,101],{"type":83,"name":84,"description":85,"armGroupLabels":86,"otherNames":46},"BEHAVIORAL","Text Messages (TM+)","A message informs the participants that a Registered Nurse (RN) from the Hub will call them about shared decision making (SDM) and LCS.",[53,58,63,68],{"type":83,"name":88,"description":89,"armGroupLabels":90,"otherNames":91},"Chatbot (CA)","Access to a chatbot for frequently asked questions about LCS",[58,68,77,72],[92],"Chatbot",{"type":83,"name":94,"description":95,"armGroupLabels":96,"otherNames":46},"Video (VID)","An educational video about LCS",[63,68],{"type":83,"name":98,"description":99,"armGroupLabels":100,"otherNames":46},"Reactive Patient Navigation (RPN)","RPN to help complete the LCS appointment. RPN requires the participant to initiate the PN request",[72],{"type":83,"name":102,"description":103,"armGroupLabels":104,"otherNames":46},"Proactive Patient Navigation (PPN)","Proactive patient navigation to help complete the LCS appointment. PPN does not require the participant to initiate the PN request and instead is a proactive call to the participant.",[77],[106],{"name":107,"affiliation":108,"role":109},"David Wetter, PhD, MS","Huntsman Cancer Institute","PRINCIPAL_INVESTIGATOR",[111],{"name":112,"role":113,"phone":114,"phoneExt":46,"email":115},"Indy Li, MS","CONTACT","801-213-5697","Indy.li@hci.utah.edu",[117],{"facility":118,"status":46,"city":119,"state":120,"zip":121,"country":122,"countryCode":123,"cosmosGeoPoint":124,"geoPoint":129,"contacts":130},"Huntsman Cancer Institute\u002FUniversity of Utah","Salt Lake City","Utah","84112","United States","US",{"type":125,"coordinates":126},"Point",[127,128],-111.89105,40.76078,{"lat":128,"lon":127},[131,134],{"name":107,"role":113,"phone":132,"phoneExt":46,"email":133},"801-213-6178","David.Wetter@hci.utah.edu",{"name":107,"role":109,"phone":46,"phoneExt":46,"email":46},{"type":136,"investigatorFullName":46,"investigatorTitle":46,"investigatorAffiliation":46,"oldNameTitle":46,"oldOrganization":46},"SPONSOR",[138,141],{"name":139,"class":140},"National Cancer Institute (NCI)","NIH",{"name":108,"class":6},"100638807","population-health-management--increase-lung-cancer-screening-in-community-health-centers-lungsmart-100638807",false,"NCT07599943","Population Health Management -Increase Lung Cancer Screening in Community Health Centers (LungSMART)","Population Health Management Approaches to Increase Lung Cancer Screening in Community Health Centers - LungSMART UH3 Clinical Trial","LungSMART","Inclusion Criteria:\n\n* Is currently a patient at participating CHCs\n* Speak English or Spanish\n* Current or former tobacco smoker\n* Male or Female\n* Age 50-80\n* Electronic health records indicate they have not opted out of receiving text contact from the clinic\n* Has a phone that can receive text messages\n\nExclusion Criteria:\n\n* Persons with lung cancer or who have previously participated in a Shared Decision Making discussion with a health provider regarding lung cancer or have completed LCS.",true,"ALL","50 Years","80 Years",{"count":155,"type":156},18894,"ESTIMATED","INTERVENTIONAL",[159],"NA","The long-term goal of Lung Sequential Multiple Assignment Randomized Trial (LungSMART) Utah is to increase the reach of Low-Dose Computed Tomography (LDCT) screening for lung cancer (hereafter referred to as Lung Cancer Screening or LCS) at scale in low-resource healthcare settings.",[162],"Lung Cancer","NOT_YET_RECRUITING","2026-09-29",{"date":166,"type":167},"2026-10-02","ACTUAL",{"date":169,"type":156},"2026-10",{"date":171,"type":156},"2030-04",{"name":5,"class":6},1]